Clearside Wins Health Canada Approval for Xipere Eye Therapy

Health Canada has approved Clearside Biomedical’s Xipere, a triamcinolone acetonide injectable suspension administered with the company’s SCS Microinjector, for the treatment of macular edema associated with uveitis. The decision makes Canada the latest market to clear the suprachoroidal-space therapy after the United States, Australia and Singapore. Xipere is licensed to Bausch + Lomb for commercialization in the United States and Canada, while Beijing-based Arctic Vision holds rights in Greater China and several Asia-Pacific territories, where regulatory review is ongoing. The approval extends validation of Clearside’s proprietary suprachoroidal delivery platform, designed to target the back of the eye and limit off-target exposure. Investors welcomed the regulatory milestone, sending Clearside shares up roughly 77% in pre-market U.S. trading on Wednesday.